Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation.

CPT: pharmacometrics & systems pharmacology - 1 May 2026

Mitra Amitava, Yang Xiaoyan, Ortiz Roberto H, Jomphe Claudia, Leoni Mollie, Gosselin Nathalie H

Abstract excerpt

Ziftomenib, a potent, highly selective, oral menin inhibitor, has demonstrated significant clinical benefit and deep responses in relapsed and/or refractory (R/R) nucleophosmin 1-mutated (NPM1-m) acute myeloid leukemia (AML) patients. Here we present data from analyses conducted to characterize ziftomenib pharmacokinetics (PK) in healthy volunteers and R/R AML patients and exposure-response (ER) relationships in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Models, Biological

Share to Mutation

Share to Nuclear Proteins

Share to Nucleophosmin

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 42081323
DOI: 10.1002/psp4.70244
PMCID: PMC13138490

Genes

NPM1
KMT2A

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation.PMID 42081323Read ↗

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.Semantic proximity Read ↗

Ziftomenib: First Approval.Semantic proximity Read ↗

P504: UPDATED DATA FOR ZIFTOMENIB IN PATIENTS WITH NPM1-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIASemantic proximity Read ↗

Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.Semantic proximity Read ↗

Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.Semantic proximity Read ↗

Menin Inhibitors: A New Era of Targeted Therapies in Acute Myeloid Leukemia.Semantic proximity Read ↗

Menin inhibitors in KMT2A-rearranged and NPM1-mutated acute leukemia: A scoping review of safety and efficacySemantic proximity Read ↗

Activity of menin inhibitor ziftomenib (KO-539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1Semantic proximity Read ↗

The promise of menin inhibitors: from approval to triplet regimens.Semantic proximity Read ↗

Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A-r and NPM1c AML.Semantic proximity Read ↗

Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.Semantic proximity Read ↗

Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.